Boston Life Sciences Announces Manufacturing Agreement for Altropane; MDS Nordion to Supply cGMP Altropane for Regulatory Filings.Business Editors/Health & Medical Writers BIOWIRE2K BOSTON--(BW HealthWire)--Aug. 14, 2000 Boston Life Sciences, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :BLSI) announced that the Company has signed an agreement with MDS MDS, n See temporomandibular pain-dysfunction syndrome. MDS 1 Maternal deprivation syndrome, see there 2 Myelodysplastic syndrome, see there Nordion, Inc. of Ottawa, Canada to supply Altropane(TM) for BLSI's regulatory filing seeking marketing approval for the Parkinson's diagnostic agent. Part of the agreement calls for MDS Nordion to also manufacture Altropane for the commercial market if and when Altropane is approved. BLSI recently announced the successful results of its Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the for the use of Altropane to diagnose early Parkinson's Disease. In addition to the announcement of this manufacturing agreement, BLSI also stated that enrollment in its Phase II trial using Altropane to diagnose Attention Deficit Hyperactivity Disorder attention deficit hyperactivity disorder (ADHD), formerly called hyperkinesis or minimal brain dysfunction, a chronic, neurologically based syndrome characterized by any or all of three types of behavior: hyperactivity, distractibility, and impulsivity. has just been completed. "We are delighted to establish this relationship with MDS Nordion for manufacturing of Altropane. MDS Nordion is the recognized pre-eminent producer of 123Iodine in North America, and has a high-quality manufacturing facility for producing finished radiopharmaceuticals. We regard MDS Nordion as a top-flight choice to manufacture Altropane for the Parkinson's Disease as well as the ADHD Attention-Deficit/Hyperactivity Disorder (ADHD) Definition Attention-deficit/hyperactivity disorder (ADHD) is a developmental disorder characterized by distractibility, hyperactivity, impulsive behaviors, and the inability to remain focused on tasks or indications," stated Marc Lanser, MD, Chief Scientific Officer of BLSI. MDS Nordion (www.mds.nordion.com) specializes in radioisotopes, radiation, and related technologies used to diagnose, prevent and treat disease. MDS Nordion is part of MDS Inc., (TSE See Tokyo Stock Exchange. TSE 1. See Tokyo Stock Exchange (TSE). 2. See Toronto Stock Exchange (TSE). :MDS)(NYSE NYSE See: New York Stock Exchange :MDZ), an international health and life sciences company based in Canada. MDS Nordion provides laboratory testing, imaging agents for nuclear medicine testing, sterilization systems for medical and consumer products, research services to speed the discovery and development of new drugs, therapy systems for planning and delivery of cancer treatment, analytical instruments to assist in the development of new drugs, and medical/surgical supplies. BLSI is developing novel diagnostics and therapeutics for Parkinson's Disease (PD) and Attention Deficit Hyperactivity Disorder (ADHD) as well as treatments for cancer, autoimmune disease, and central nervous system disorders Nervous system disorders A satisfactory classification of diseases of the nervous system should include not only the type of reaction (congenital malformation, infection, trauma, neoplasm, vascular diseases, and degenerative, metabolic, toxic, or deficiency . BLSI's products in development include: Altropane, a radioimaging agent for the diagnosis of PD and ADHD; Troponin I, a naturally-occurring anti-angiogenesis factor for the treatment of solid tumors; AF-1 and Inosine inosine /in·o·sine/ (I) (in´o-sen) a purine nucleoside containing the base hypoxanthine and the sugar ribose, which occurs in transfer RNAs and as an intermediate in the degradation of purines and purine nucleosides to uric acid and in , nerve growth factors for the treatment of acute and chronic CNS See Continuous net settlement. CNS See continuous net settlement (CNS). disorders; novel therapies for the treatment of PD and ADHD; and transcription factors that may control the expression of molecules associated with autoimmune disease and allergies. Statements made in this press release other than statements of historical fact represent forward-looking statements. Such statements include, without limitation, statements regarding expectations or beliefs as to future results or events, such as the expected timing and results of clinical trials, discussions with regulatory agencies, schedules of IND, NDA and all other regulatory submissions, the timing of product introductions, the possible approval of products, and the market size and possible advantages of the Company's products. All such forward-looking statements involve substantial risks and uncertainties, and actual results may vary materially from these statements. Factors that may affect future results include: the availability and adequacy of financial resources, the ability to obtain intellectual property protection, delays in the regulatory or development processes, results of scientific data from clinical trials, the outcome of discussions with potential partners, regulatory decisions, market acceptance of the Company's products, and other possible risks and uncertainties that have been noted in reports filed by the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion